<- Go Home
BioLineRx Ltd.
BioLineRx Ltd., a commercial stage biopharmaceutical company, develops and commercializes therapeutics for oncology and rare diseases. The company’s pipeline includes APHEXDA (motixafortide), a peptide that is in Phase 1 clinical trial for the treatment of sickle cell disease, and Phase 2b clinical trial for the treatment of pancreatic cancer, as well as completed Phase 3 clinical trial for the treatment of multiple myeloma. It also develops BL-5010, a pen-like applicator containing an acidic aqueous solution for the non-surgical removal of skin lesions. BioLineRx Ltd. was incorporated in 2003 and is headquartered in Hevel Modi'in, Israel.
Market Cap
ILS 25.6M
Volume
869.8K
Cash and Equivalents
ILS 8.8M
EBITDA
-ILS 25.5M
Tax Rate Collected
N/A
Tax Rate Ratio
N/A
Gross Profit
ILS 15.1M
Profit Margin
68.78%
52 Week High
ILS 0.12
52 Week Low
ILS 0.02
Dividend
N/A
Price / Book Value
3.01
Price / Earnings
-1.22
Price / Tangible Book Value
-5.40
Enterprise Value
ILS 26.1M
Enterprise Value / EBITDA
-1.04
Operating Income
-ILS 27.8M
Return on Equity
184.09%
Return on Assets
-32.96
Cash and Short Term Investments
ILS 29.2M
Debt
ILS 29.6M
Equity
ILS 8.5M
Revenue
ILS 22.0M
Unlevered FCF
-ILS 14.7M
Sector
Biotechnology
Category
N/A